PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia

Nature Cell Biology

Volumn 18, Issue 7, 2016, Pages 803-813

  Banh, Robert S ^a,b,c   Iorio, Caterina ^b   Marcotte, Richard ^b   Xu, Yang ^a,b,c   Cojocari, Dan ^a,b   Rahman, Anas Abdel ^d,e   Pawling, Judy ^d   Zhang, Wei ^a   Sinha, Ankit ^a,b   Rose, Christopher M ^f   Isasa, Marta ^f   Zhang, Shuang ^c   Wu, Ronald ^a,b   Virtanen, Carl ^b   Hitomi, Toshiaki ^g   Habu, Toshiyuki ^g   Sidhu, Sachdev S ^a   Koizumi, Akio ^g   Wilkins, Sarah E ^h   Kislinger, Thomas ^a,b   Gygi, Steven P ^f   Schofield, Christopher J ^h   Dennis, James W ^d   Wouter, Bradly G ^a,b   Neel, Benjamin G ^b,c   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f HARVARD MEDICAL SCHOOL   (United States)

^g KYOTO UNIVERSITY   (Japan)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA KGDD PROTEIN; DIOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE PHOSPHATASE 1B; RNF213 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ALPHA KETOGLUTARATE DEPENDENT DIOXYGENASE FTO; PTPN1 PROTEIN, HUMAN; PTPN1 PROTEIN, MOUSE; RNF213 PROTEIN, HUMAN; RNF213 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CARCINOGENICITY; CELL DEATH; GENE SILENCING; HYPOXIA; IN VITRO STUDY; MOUSE; NON MITOCHONDRIAL OXYGEN CONSUMPTION; NONHUMAN; ONCOLOGICAL PARAMETERS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REGULATORY MECHANISM; RNF213 GENE; SURVIVAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; TUMOR SURVIVAL; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL HYPOXIA; FEMALE; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; PHYSIOLOGY; PROTO ONCOGENE;

ADENOSINE TRIPHOSPHATASES; ALPHA-KETOGLUTARATE-DEPENDENT DIOXYGENASE FTO; ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; FEMALE; GENES, ERBB-2; HUMANS; MICE; MITOCHONDRIA; OXYGEN CONSUMPTION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; UBIQUITIN-PROTEIN LIGASES;

EID: 84975318750     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3376     Document Type: Article

References (62)

1. Bertout J. A, Patel S. A, & Simon M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008).
2. Papandreou I, Cairns R. A, Fontana L, Lim A. L, & Denko N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197 (2006).
3. Ma X. M, & Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. 10, 307-318 (2009).
4. Laplante M, & Sabatini D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
5. Ron D, & Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519-529 (2007).
6. Loenarz C, & Schofield C. J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat. Chem. Biol. 4, 152-156 (2008).
7. Schofield C. J, & Ratcliffe P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. 5, 343-354 (2004).
8. Hewitson K. S, Granatino N, Welford R. W, McDonough M. A, & Schofield C. J. Oxidation by 2-oxoglutarate oxygenases: non-haem iron systems in catalysis and signalling. Phil. Transact. A 363, 807-828 (2005), discussion 1035-1040.
9. Schofield C. J, & Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol. 9, 722-731 (1999).
10. Kuiper C, & Vissers M. C. Ascorbate as a co-factor for Fe-and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 4, 359 (2014).
11. Elchebly M, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548 (1999).
12. Zabolotny J. M, et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2, 489-495 (2002).
13. Klaman L. D, et al. Increased energy expenditure, decreased adiposity, and tissuespecific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20, 5479-5489 (2000).
14. Bettaieb A, et al. Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation. J. Biol. Chem. 288, 17360-17371 (2013).
15. Krishnan N, Fu C, Pappin D. J, & Tonks N. K. H2S-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci. Signal. 4, ra86 (2011).
16. Stuible M, Doody K. M, & Tremblay M. L. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev. 27, 215-230 (2008).
17. Comprehensive molecular portraits of human breast tumours Nature 490 61-70 (2012).
18. Wiener J. R, et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl Cancer Inst. 86, 372-378 (1994).
19. Bentires-Alj M, & Neel B. G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67, 2420-2424 (2007).
20. Julien S. G, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39, 338-346 (2007).
21. Kim J. S. Moyamoya disease: epidemiology, clinical features, and diagnosis. J. Stroke 18, 2-11 (2016).
22. Krishnan N, et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat. Chem. Biol. 10, 558-566 (2014).
23. Balavenkatraman K. K, et al. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol. Cancer Res. 9, 1377-1384 (2011).
24. Wiesmann C, et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11, 730-737 (2004).
25. Anso E, et al. Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab. 1, 7 (2013).
26. McDonough M. A, et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J. Am. Chem. Soc. 127, 7680-7681 (2005).
27. Chowdhury R, et al. Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem. Biol. 8, 1488-1496 (2013).
28. Yan L, Colandrea V. J, & Hale J. J. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin. Ther. Pat. 20, 1219-1245 (2010).
29. Tiganis T, & Bennett A. M. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J. 402, 1-15 (2007).
30. Flint A. J, Tiganis T, Barford D, & Tonks N. K. Development of substratetrapping mutants to identify physiological substrates of protein tyrosine phosphatases. Proc. Natl Acad. Sci. USA 94, 1680-1685 (1997).
31. Gentile A, et al. Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene 27, 5590-5598 (2008).
32. Mertins P, et al. Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol. Cell. Proteomics 7, 1763-1777 (2008).
33. Liu W, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 6, e22542 (2011).
34. Kim W, et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325-340 (2011).
35. Weinberg D. G, et al. Moyamoya disease: a review of histopathology, biochemistry, and genetics. Neurosurg. Focus 30, E20 (2011).
36. Lutterman J, Scott M, Nass R, & Geva T. Moyamoya syndrome associated with congenital heart disease. Pediatrics 101, 57-60 (1998).
37. Comprehensive molecular characterization of human colon and rectal cancer Nature 487 330-337 (2012).
38. Wiesmann C, et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11, 730-737 (2004).
39. Liu W, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 6, e22542 (2011).
40. Ingber D, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
41. Bentires-Alj M, & Neel B. G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67, 2420-2424 (2007).
42. Ran F. A, et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 2281-2308 (2013).
43. van den Beucken T, et al. Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J. Biol. Chem. 284, 24204-24212 (2009).
44. Abdel Rahman A. M, Ryczko M, Pawling J, & Dennis J. W. Probing the hexosamine biosynthetic pathway in human tumor cells by multitargeted tandem mass spectrometry. ACS Chem. Biol. 8, 2053-2062 (2013).
45. Abdel Rahman A. M, et al. Golgi N-glycan branching Nacetylglucosaminyltransferases I, V and VI promote nutrient uptake and metabolism. Glycobiology 25, 225-240 (2015).
46. Abdel Rahman A. M, Pawling J, Ryczko M, Caudy A. A, & Dennis J. W. Targeted metabolomics in cultured cells and tissues by mass spectrometry: method development and validation. Anal. Chim. Acta 845, 53-61 (2014).
47. Wu X, et al. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-Associated RAF1 mutants. Mol. Cell. Biol. 32, 3872-3890 (2012).
48. Gross S, et al. Cancer-Associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010).
49. Ward P. S, et al. The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting -ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010).
50. Sinha A, Ignatchenko V, Ignatchenko A, Mejia-Guerrero S, & Kislinger T. Indepth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochem. Biophys. Res. Commun. 445, 694-701 (2014).
51. Cox J, & Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
52. Udeshi N. D, et al. Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol. Cell. Proteomics 11, 148-159 (2012).
53. Thompson A, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895-1904 (2003).
54. Senko M. W, et al. Novel parallelized quadrupole/linear ion trap/Orbitrap tribrid mass spectrometer improving proteome coverage and peptide identification rates. Anal. Chem. 85, 11710-11714 (2013).
55. Ting L, Rad R, Gygi S. P, & Haas W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods 8, 937-940 (2011).
56. McAlister G. C, et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150-7158 (2014).
57. Eng J. K, McCormack A. L, & Yates J. R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976-989 (1994).
58. Elias J. E, & Gygi S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207-214 (2007).
59. Huttlin E. L, et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143 1174-1189 (2010).
60. Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
61. Maere S, Heymans K, & Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448-3449 (2005).
62. Sherman B. T, et al. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 8, 426 (2007).